Related Experiment Video
Updated: Dec 15, 2025
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.6K
Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD
Nathan R Stein1, Leila R Zelnick2, Amanda H Anderson3
1Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Kidney International Reports
|July 11, 2020
Summary
In chronic kidney disease (CKD), novel biomarker growth differentiation factor 15 (GDF-15) and established cardiac biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT) correlate with subclinical cardiac changes. These findings may illuminate pathways to heart failure.
Area of Science:
- Cardiology
- Nephrology
- Biomarker Research
Background:
- Subclinical cardiac structural and functional changes in chronic kidney disease (CKD) precede clinical heart failure (HF).
- Cardiac biomarkers may reflect these underlying pathophysiological alterations.
- Investigating novel biomarkers alongside established ones offers insight into CKD-related cardiovascular disease.
Purpose of the Study:
- To assess associations between established (NT-proBNP, hsTnT) and novel (GDF-15, Gal-3, sST-2) biomarkers with echocardiographic measures of cardiac structure and function in CKD patients.
- To explore the relationship between these biomarkers and subclinical cardiovascular disease in mild to moderate CKD.
Main Methods:
- Cross-sectional analysis of 2101 participants with mild to moderate CKD from the Chronic Renal Insufficiency Cohort (CRIC) study.
- Biomarker levels at baseline were correlated with echocardiographic measurements (LVMI, LVESV, LVEDV, LVEF, LAD) obtained one year later.
- Multivariable linear regression models were used to adjust for relevant covariates.
Main Results:
- Growth differentiation factor 15 (GDF-15) showed significant associations with increased left ventricular mass index (LVMI), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV).
- These GDF-15 associations were attenuated after adjusting for NT-proBNP and hsTnT.
- Established biomarkers NT-proBNP and hsTnT were significantly associated with all measured echocardiographic parameters, while Gal-3 and sST-2 showed no significant associations.
Conclusions:
- In CKD patients, GDF-15, NT-proBNP, and hsTnT are associated with echocardiographic evidence of subclinical cardiovascular disease.
- These biomarkers may collectively indicate biological pathways contributing to the progression of heart failure in CKD.
- Further research is warranted to elucidate the specific roles of these biomarkers in CKD-associated cardiotoxicity.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
441
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
441
01:24Chronic Kidney Disease II: Clinical Manifestations
437
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
437
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
421
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
421
01:28Chronic Kidney Disease III: Interprofessional Care
254
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
254
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
669
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
669
01:18Chronic Kidney Disease IV: Nursing Management
207
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
207